Zighelboim, I., Wright, J. D., Powell, M. A., Case, A. S., Eisenhauer, E. L., Cohn, D. E., … Rader, J. S. (2010). Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer. Journal of Clinical Oncology, 28(15_suppl), TPS252–TPS252. https://doi.org/10.1200/jco.2010.28.15_suppl.tps252

Zighelboim, I., J. D. Wright, M. A. Powell, A. S. Case, E. L. Eisenhauer, D. E. Cohn, F. A. Valea, A. A. Secord, L. T. Lippmann, and J. S. Rader. “Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): TPS252–TPS252. https://doi.org/10.1200/jco.2010.28.15_suppl.tps252.

Zighelboim I, Wright JD, Powell MA, Case AS, Eisenhauer EL, Cohn DE, et al. Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer. Journal of Clinical Oncology. 2010 May 20;28(15_suppl):TPS252–TPS252.

Zighelboim, I., et al. “Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer.” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2010, pp. TPS252–TPS252. Crossref, doi:10.1200/jco.2010.28.15_suppl.tps252.

Zighelboim I, Wright JD, Powell MA, Case AS, Eisenhauer EL, Cohn DE, Valea FA, Secord AA, Lippmann LT, Rader JS. Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010 May 20;28(15_suppl):TPS252–TPS252.